course -万博官网登录

home>about livzon>course
from 2020 to now
the enterprise develops rapidly and marches into the international market
  • many industrial innovative products are coming soon

  • covid-19 antibody detection reagent and many other products go out of china and enter the international market


2016-2019
the enterprise made the future layout based on its advantages
  • expanded r&d team and introduced new r&d technology

  • realized whole-line cold chain logistics for the first time nationwide

  • completed the development and started the clinical test of many industry-leading project, such as irradiator, multiple, hiv, etc.

  • be recognized as provincial level innovation and industrialization demonstration enterprise for several times

  • established "guangdong postdoctoral innovation practice base"

  • be approved as a national “post-doctoral research center”

  • established suzhou r&d center

  • moved into the new industrial park with a floor area of 23,000 m2



1998-2015
the enterprise restructured and started a new development way
  • cooperated with many international ivd enterprises, such as unipath, fujirebro, siemens, mp, etc.

  • the market share of aids confirmation reagents reached 80%, and the market share of drug concentration detection reached 50%,many self-developed products occupied over 60% of the market share.many products became reference methods for disease detection, such as mycoii and tp.pa.



1989-1998
the enterprise was newly established by the group
  • 1989, the first subsidiary of livzon pharmaceutical group inc.

  • obtained pharmaceutical manufacturing license

  • many products were successfully developed and marketed, including hbv, hiv, hcv elisa reagents



网站地图